{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:37:15Z","timestamp":1793288235453,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Autoimmune encephalitis (AE) is a group of neuroinflammatory disorders with variable clinical outcomes. Despite the identification of specific neuronal autoantibodies, their clinical presentation and outcomes were significantly variable in clinical practice, suggesting the influence of additional factors beyond the primary autoantibody. Systemic and Organ-Specific autoantibodies (SAOS-Ab) are frequently detected in AE patients, but their clinical role remains incompletely characterized. We hypothesized that the coexistence of SAOS-Ab in AE was associated with a more severe disease course and higher relapse risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, retrospective cohort study, we analyzed 218 AE patients from four Chinese tertiary centers (January 2018-October 2022). AE patients were stratified into SAOS-Ab-positive and SAOS-Ab-negative groups based on serological testing. We compared demographic, clinical, and immunological features. The primary outcomes were disease severity at onset (measured by clinical assessment scale in autoimmune encephalitis [CASE] scores), short-term functional outcome (measured by modified Rankin scale [mRS] scores), and 24-month relapse risk. Multivariable logistic and Cox regression analyses were employed to identify independent predictors of poor outcome and relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A high prevalence (57.3%, 125\/218) of SAOS-Ab was observed. The SAOS-Ab-positive group had a higher female proportion (55.2% vs 35.5%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.004), and elevated serum B cell proportions (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0027), IgG (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001) and IgM (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0334). Clinically, these patients had higher initial CASE scores (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001), greater ICU admission rates (21.6% vs 7.5%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005), and more frequent poor functional outcomes at discharge (mRS \u2265 3; 47.2% vs 26.9%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002). The 24-month relapse rate was significantly higher in the SAOS-Ab-positive group (29.8% vs 13.2%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0043). After adjustment, SAOS-Ab positivity remained an independent risk factor for relapse (adjusted HR 2.270, 95% CI 1.174-4.387,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SAOS-Ab is a prevalent and clinically relevant biomarker in AE, associated with distinct immunologic profiles, more severe disease, and significantly increased relapse risk. These findings support the integration of SAOS-Ab testing into AE management to facilitate early risk stratification and more frequent follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1759213","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:59Z","timestamp":1768973879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic and organ-specific autoantibodies and worse outcomes in autoimmune encephalitis: a multicenter cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yang","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Song","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganqin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaopeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Gaozhou People\u2019s Hospital, Guangdong Medical University","place":["Gaozhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102339","article-title":"The immunobiology of autoimmune encephalitides","volume":"104","author":"Alexopoulos","year":"2019","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000208026","article-title":"Immunotherapy in autoimmune encephalitis: so many options, so few guidelines","volume":"101","author":"Srivastava","year":"2023","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01178-4","article-title":"Antibody therapies in autoimmune encephalitis","volume":"19","author":"Smets","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/10408363.2023.2247482","article-title":"General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis","volume":"61","author":"Masciocchi","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4154","article-title":"Autoimmune encephalitis-misdiagnosis, misconceptions, and how to avoid them","volume":"80","author":"Dalmau","year":"2023","journal-title":"JAMA Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858766","article-title":"Coexistence of multiple anti-neuronal antibodies in autoimmune encephalitis in China: A multi-center study","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4251","article-title":"Autoimmune encephalitis misdiagnosis in adults","volume":"80","author":"Flanagan","year":"2023","journal-title":"JAMA Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in mog-igg1-associated disorders versus aqp4-igg+ Nmosd","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1749-6632.1965.tb18939.x","article-title":"Organ-specific autoantibodies","volume":"124","author":"Witebsky","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12714","article-title":"Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica","volume":"23","author":"Masuda","year":"2016","journal-title":"Eur J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.45.12.2299-c","article-title":"Antinuclear antibodies in multiple sclerosis","volume":"45","author":"Aisen","year":"1995","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00117","article-title":"Serum systemic autoantibodies in anti-N-methyl-D-aspartate receptor encephalitis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.975583","article-title":"Presence of anti-nuclear antibody associated with worse clinical outcomes of anti-nmdar encephalitis","volume":"13","author":"Lei","year":"2022","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113694-20221020-00779","article-title":"Chinese Society of Neuroimmunology. Expert consensus on the detection of antibodies associated with autoimmune diseases of the central nervous system 2022","volume":"56","author":"Bu","year":"2023","journal-title":"Chin J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25421","article-title":"Development of the clinical assessment scale in autoimmune encephalitis","volume":"85","author":"Lim","year":"2019","journal-title":"Ann Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000258355.23810.c6","article-title":"Outcomes validity and reliability of the modified rankin scale: implications for stroke clinical trials: A literature review and synthesis","volume":"38","author":"Banks","year":"2007","journal-title":"Stroke"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8418-7","article-title":"Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (Multiple autoimmune syndromes and overlap syndromes): A challenge for the autoimmunologist","volume":"56","author":"Tozzoli","year":"2013","journal-title":"Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102887","article-title":"Systemic lupus erythematosus-complicating immune thrombocytopenia: from pathogenesis to treatment","volume":"132","author":"Jiang","year":"2022","journal-title":"J Autoimmun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.02.002","article-title":"Common mechanisms of autoimmune diseases (the autoimmune tautology)","volume":"11","author":"Anaya","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.049","article-title":"The diagnosis and clinical significance of polyautoimmunity","volume":"13","author":"Anaya","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02279","article-title":"Sex hormones in acquired immunity and autoimmune disease","volume":"9","author":"Moulton","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106632","article-title":"Lymphocytes in autoimmune encephalitis: pathogenesis and therapeutic target","volume":"200","author":"Chen","year":"2024","journal-title":"Neurobiol Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.444","article-title":"Nmdar encephalitis: passive transfer from man to mouse by a recombinant antibody","volume":"4","author":"Malviya","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.10.014","article-title":"Prognosticating autoimmune encephalitis: A systematic review","volume":"96","author":"Broadley","year":"2019","journal-title":"J Autoimmun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213532","article-title":"Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: A single-center cohort study in China","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-nmda receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1759213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:38:05Z","timestamp":1768973885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1759213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1759213"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1759213","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1759213"}}